219 related articles for article (PubMed ID: 29331383)
1. Population Pharmacokinetics of High-Dose Methotrexate in Patients With Primary Central Nervous System Lymphoma.
Mei S; Li X; Jiang X; Yu K; Lin S; Zhao Z
J Pharm Sci; 2018 May; 107(5):1454-1460. PubMed ID: 29331383
[TBL] [Abstract][Full Text] [Related]
2. Urine volume to hydration volume ratio is associated with pharmacokinetics of high-dose methotrexate in patients with primary central nervous system lymphoma.
Isono T; Hira D; Morikochi A; Fukami T; Ueshima S; Nozaki K; Terada T; Morita SY
Pharmacol Res Perspect; 2021 Dec; 9(6):e00883. PubMed ID: 34664791
[TBL] [Abstract][Full Text] [Related]
3. The prognostic value of serum methotrexate area under curve in elderly primary CNS lymphoma patients.
Kasenda B; Rehberg M; Thürmann P; Franzem M; Veelken H; Fritsch K; Schorb E; Finke J; Lebiedz D; Illerhaus G
Ann Hematol; 2012 Aug; 91(8):1257-64. PubMed ID: 22456893
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Body Size, Morphomics, and Kidney Function as Covariates of High-Dose Methotrexate Clearance in Obese Adults with Primary Central Nervous System Lymphoma.
Pai MP; Debacker KC; Derstine B; Sullivan J; Su GL; Wang SC
Pharmacotherapy; 2020 Apr; 40(4):308-319. PubMed ID: 32090349
[TBL] [Abstract][Full Text] [Related]
5. Influence of methotrexate exposure on outcome in patients treated with MBVP chemotherapy for primary central nervous system lymphoma.
Blasco H; Senecal D; Le Gouge A; Pinard E; Benz-de Bretagne I; Colombat P; Hulot JS; Chatelut E; Le Guellec C
Br J Clin Pharmacol; 2010 Sep; 70(3):367-75. PubMed ID: 20716237
[TBL] [Abstract][Full Text] [Related]
6. Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma?
Khan RB; Shi W; Thaler HT; DeAngelis LM; Abrey LE
J Neurooncol; 2002 Jun; 58(2):175-8. PubMed ID: 12164690
[TBL] [Abstract][Full Text] [Related]
7. Delayed methotrexate elimination in a patient with primary central nervous system lymphoma: A case report.
Urata S; Yoshikawa N; Saito K; Tazaki T; Ohno R; Takeshima H; Ikeda R
J Clin Pharm Ther; 2021 Dec; 46(6):1796-1799. PubMed ID: 34008211
[TBL] [Abstract][Full Text] [Related]
8. Clinical utility and pharmacology of high-dose methotrexate in the treatment of primary CNS lymphoma.
Green MR; Chowdhary S; Lombardi KM; Chalmers LM; Chamberlain M
Expert Rev Neurother; 2006 May; 6(5):635-52. PubMed ID: 16734512
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of methotrexate in Mexican pediatric patients with acute lymphoblastic leukemia.
Medellin-Garibay SE; Hernández-Villa N; Correa-González LC; Morales-Barragán MN; Valero-Rivera KP; Reséndiz-Galván JE; Ortiz-Zamudio JJ; Milán-Segovia RDC; Romano-Moreno S
Cancer Chemother Pharmacol; 2020 Jan; 85(1):21-31. PubMed ID: 31673826
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of polyglutamylation in primary central nervous system lymphoma.
Shinojima N; Fujimoto K; Makino K; Todaka K; Yamada K; Mikami Y; Oda K; Nakamura K; Jono H; Kuratsu JI; Nakamura H; Yano S; Mukasa A
Acta Neuropathol Commun; 2018 Feb; 6(1):15. PubMed ID: 29475458
[TBL] [Abstract][Full Text] [Related]
11. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial.
Joerger M; Huitema AD; Krähenbühl S; Schellens JH; Cerny T; Reni M; Zucca E; Cavalli F; Ferreri AJ
Br J Cancer; 2010 Feb; 102(4):673-7. PubMed ID: 20125159
[TBL] [Abstract][Full Text] [Related]
12. [Effects of infusion duration of high-dose methotrexate on cerebrospinal fluid drug levels in lymphoma patients].
Lin XB; Zhou NN; Li S; Cai QQ; Xia ZJ; Liao H; Gao Y; Huang HQ
Ai Zheng; 2008 Oct; 27(10):1100-5. PubMed ID: 18851792
[TBL] [Abstract][Full Text] [Related]
13. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of high-dose methotrexate in Chinese pediatric patients with medulloblastoma.
Shi ZY; Liu YO; Gu HY; Xu XQ; Yan C; Yang XY; Yan D
Biopharm Drug Dispos; 2020 Mar; 41(3):101-110. PubMed ID: 32017134
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetic study of methotrexate in children with acute lymphoblastic leukemia.
Zhang C; Zhai S; Yang L; Wu H; Zhang J; Ke X
Int J Clin Pharmacol Ther; 2010 Jan; 48(1):11-21. PubMed ID: 20040335
[TBL] [Abstract][Full Text] [Related]
16. Calculated versus measured creatinine clearance for dosing methotrexate in the treatment of primary central nervous system lymphoma.
Gerber DE; Grossman SA; Batchelor T; Ye X
Cancer Chemother Pharmacol; 2007 May; 59(6):817-23. PubMed ID: 16972068
[TBL] [Abstract][Full Text] [Related]
17. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysis.
Kasenda B; Ferreri AJ; Marturano E; Forst D; Bromberg J; Ghesquieres H; Ferlay C; Blay JY; Hoang-Xuan K; Pulczynski EJ; Fosså A; Okoshi Y; Chiba S; Fritsch K; Omuro A; O'Neill BP; Bairey O; Schandelmaier S; Gloy V; Bhatnagar N; Haug S; Rahner S; Batchelor TT; Illerhaus G; Briel M
Ann Oncol; 2015 Jul; 26(7):1305-13. PubMed ID: 25701456
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia.
Aumente D; Buelga DS; Lukas JC; Gomez P; Torres A; García MJ
Clin Pharmacokinet; 2006; 45(12):1227-38. PubMed ID: 17112298
[TBL] [Abstract][Full Text] [Related]
19. High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma.
Jahnke K; Korfel A; Martus P; Weller M; Herrlinger U; Schmittel A; Fischer L; Thiel E;
Ann Oncol; 2005 Mar; 16(3):445-9. PubMed ID: 15653703
[TBL] [Abstract][Full Text] [Related]
20. Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas.
Ferreri AJ; Guerra E; Regazzi M; Pasini F; Ambrosetti A; Pivnik A; Gubkin A; Calderoni A; Spina M; Brandes A; Ferrarese F; Rognone A; Govi S; Dell'Oro S; Locatelli M; Villa E; Reni M
Br J Cancer; 2004 Jan; 90(2):353-8. PubMed ID: 14735176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]